As a physician who prescribes GLP-1 medications like Ozempic, Wegovy, semaglutide, and tirzepatide, I explain why increasing ...

Hims & Hers and Novo Nordisk’s very public eight-month-long feud over GLP-1 drugs just came to an end. Today, the two former ...

GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301Proprietary Forzet formulation provides ...

Health news and commentary gathered by MedPage Today staff ...

A peer-reviewed study of more than 46,000 older adults with type 2 diabetes found that patients who started GLP-1 receptor agonist drugs faced an 11 percent higher risk of fragility fractures compared ...

New research suggests GLP-1 drugs may increase the risk of bone and tendon injuries and other conditions, including ...

Hers is currently offering 20% off GLP-1 medication for eligible subscribers who pay over $500 for weight-loss services.

The FDA has issued warnings to 30 telehealth companies for making false or misleading claims regarding compounded GLP-1 ...

Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that ...

The effect was seen across a wide variety of addictive and habit-forming substances, including cocaine, opioids, alcohol, ...

Al-Aly and his colleagues found that people starting the GLP-1 drugs had lower risks of developing addiction to multiple ...